Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. (2022)

• Record Type: Journal Article
• Authors: Ueda, Tomoaki; Fukushima, Kentaro; Kusakabe, Shinsuke; Yoshida, Koki; Suga, Makiko; Nakai, Ritsuko; Koike, Midori; Hino, Akihisa; Akuta, Keigo; Toda, Jun; Nagate, Yasuhiro; Doi, Yukiko; Fujita, Jiro; Yokota, Takafumi; Hosen, Naoki
• Is Part Of: Leukemia research reports. Volume 17(2022)
• Publication Date: 2022
• Subjects: Philadelphia chromosome-positive acute lymphoblastic leukemia -- Allogeneic stem cell transplantation -- Inotuzumab ozogamicin -- Blinatumomab; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100294
• Languages: English
• ISSNs: 2213-0489

Abstract

Highlights: The outcome of R/R Ph+ALL is dismal. Single cycle of Inotuzumab ozogamicin could achieve CR without VOD/SOS. Blinatumomab could achieve and keep MRD negativity without CRS. InO-Blina is effective and safe for R/R Ph+ALL as a bridging regimen before allo-SCT. Abstract: To overcome the unfavorable outcome of refractory/relapsed (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and conduct allogeneic stem cell transplantation (allo-SCT) safely, we designed a sequential therapy involving a single cycle of Inotuzumab ozogamicin (InO) and Blinatumomab (Blina). Two heavily treated and aged patients with R/R Ph+ALL were treated with the therapy. Both of them achieved complete molecular remission without cytokine release syndrome and underwent allo-SCT without veno-occlusive disease/sinusoidal obstruction syndrome. Although appropriate central nervous system prophylaxis should be added, the InO-Blina sequential therapy is a promising strategy for treating R/R Ph+ALL as a bridging regimen before allo-SCT.